StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Nirav Chheda, Nirmal Bang Securities

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byNirav Chheda, Nirmal Bang SecuritiesHorizon: 1 year12 Nov 2026via CNBC Awaaz.

Entry₹2,300.2Inferred
Target₹2,751
Total upside +19.60%
Stop lossNot given
CMP₹2,361.71d ago
Active+2.67%+16.48%upside left 12 mo left
Follow Nirav Chheda for new callsGet alertsWatch EMCURE for new buy/sell callsGet alertsSee 3 other Long-term calls on EMCURESee 272 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 15 Nov, 3:24 am IST
18 supporting5 neutral2 opposing
Supports the BUY call (18)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·13 Nov · yesterday

Emcure raises FY27 revenue outlook above 20% after strong H1

NewsGoogle News·6 Nov · 1w ago

(opens in new tab)

Emcure Pharmaceuticals Q2FY27 Results: Standalone PAT up 111% YoY

NewsGoogle News·5 Nov · 1w ago

(opens in new tab)

3 other SEBI-registered advisors have active long-term BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·5 Nov · 1w ago

Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises

NewsHbl·4 Nov · 1w ago

(opens in new tab)
Neutral / worth noting (5)

For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.

BSE · Board Meeting·3 Nov · 2w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Nirav Chheda, Nirmal Bang Securities

Every call and its outcome